Related Experiment Video
Updated: Jun 27, 2026
08:18
A Model of Chronic Nutrient Infusion in the Rat
Published on: August 14, 2013
Genetic influences on ketogenic diet efficacy
Stacey B B Dutton1, Andrew Escayg
1Department of Human Genetics, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Epilepsia
|December 17, 2008
Summary
Genetic factors influence ketogenic diet (KD) efficacy for seizure reduction. This study observed strain-specific differences in how well the KD altered seizure thresholds in mice, suggesting genetics play a role.
Area of Science:
- Neuroscience
- Genetics
- Metabolic Disorders
Background:
- The ketogenic diet (KD) is an effective therapy for epilepsy, reducing seizure frequency by over 50% in 15-20% of patients.
- However, 10-40% of patients discontinue the KD due to poor response or adverse effects, indicating significant individual variability.
- This variability suggests that genetic factors may play a crucial role in determining the efficacy of the KD.
Purpose of the Study:
- To investigate the influence of genetic factors on the efficacy of the ketogenic diet (KD) in altering seizure thresholds.
- This study serves as a foundational step towards identifying specific genetic determinants of KD response.
Main Methods:
- The study evaluated the impact of the KD on seizure thresholds in four common inbred mouse strains: C57BL/6J, FVB/NJ, A/J, and DBA/2J.
- Strain-specific responses to the KD were analyzed to assess the role of genetic background.
Main Results:
- Significant strain-specific differences were observed in the ability of the ketogenic diet to modify seizure thresholds across the tested mouse strains.
- These findings demonstrate that the genetic makeup of an individual influences their response to the KD.
Conclusions:
- Genetic factors are likely to significantly influence the efficacy of the ketogenic diet in managing seizures.
- Further research into these genetic factors is warranted to personalize KD therapy for epilepsy and other conditions.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:22Diabetic Ketoacidosis ll: Pathophysiology
Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...